Global Molecular Cytogenetics Market Size, Share, Forecast Report, 2020-2027

Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 9 in /home/multiwpmr/public_html/report-details.php on line 448
The global molecular cytogenetics market is estimated to grow at a CAGR of more than 6% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer and increasing demand for genetic testing tools. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. 43.8 million persons were living with cancer in 2018 who were diagnosed within the last 5 years. This rising prevalence of cancer is attributing to the demand for molecular cytogenetic tools.



Fluorescence in-situ hybridization (FISH) study is acrucial tool for both diagnostics and clinical research, as well as diagnostics, in cancer and leukemia. FISH can be utilized to assess chromosomal abnormalities with fluorescent-labeled DNA probes that target specific DNA sequences. FISH-based tests and comparative genomic hybridization (CGH), and multicolor karyotyping, have been utilized in clinical applications. These tests allow whole global scanning of genomic imbalances and resolution of complex karyotypic aberrations. Cross-species array CGH analysis has been used in the identification of cancer gene.



The clinical effect of FISH is crucial, primarily in the diagnosis, prognosis and treatment decisions for hematological conditions, which facilitate the area of personalized medicine. Molecular cytogenetics enables to properly differentiate cancer-causing and normal cells, which in turn, is leading its adoption in cancer diagnostics.Further, the market has significant growth opportunity owing to the advent of next-generation sequencing (NGS) and increasing researches on personalized medicines. However, certain factors are restricting the market growth include high cost of instruments and unfavorable reimbursement policies for genomic tools.



Segmentation



The global molecular cytogenetics market is segmented based on the product, application, and end-user. Based on the product, the market is segmented into consumables, software & services, and instruments. Based on application, the market is classified into cancer, genetic disorders, and personalized medicine.Based on technique, the market is classified intofluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and Others.



Fluorescence in situ hybridization (FISH) is one of the major techniquesin molecular cytogenetics testing.



Molecular cytogenetic techniques mainly rely on FISH, which is based on the principle of complementary hybridization of labeled DNA or RNA probes with normal or abnormal nucleic acid sequences on metaphase chromosomes, interphase cells or tissue sections.FISH takes us to a colorful chromosome world,which involves a fluorescently labeled DNA probe hybridized to a specific genomic segment of interest.FISH can detect small chromosomal rearrangements that cannot be detected by conventional cytogenetic techniques. The use of FISH technique enhanced the interpretation of the numerical and complex chromosomal rearrangements, bridging the gap between conventional cytogenetics and molecular biology. Therefore, it is being significantly adopted technique in genome researches and cancer diagnostics. In genome researches, FISH enables researchers to map and visualize the genetic material in an individual's cells, including portions of genesor specific genes. This technique may be applied to understand a range of chromosomal abnormalities and other genetic mutations.



Regional Outlook



Geographically, the global molecular cytogenetics market is segmented into North America, Europe, Asia-Pacific, and Rest of the world. In 2018, North America held the largest share in the market owing to the significant prevalence of cancer, increasing funding for genome researches and significant share in life science researches in the region. In addition, the presence of major players, including Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., and Illumina, Inc. are offering a potential opportunity for the market growth in the region. These companies are focusing on introducing advanced molecular cytogenetics tools that will likely to increase their market share.



Asia-Pacific is expected to witness considerable growth during the forecast period



Asia-Pacific is estimated to show potential growth during the forecast period owing to the rising cancer incidences and government initiatives to promote awareness regarding the condition. For instance, as per the WHO, the total number of new cancer incidences reported in China was nearly 4.3 million and in India, it was nearly 1.2 million. These incidences have resulted in the number of initiatives for cancer prevention and control. For instance, In February 2017, the Chinese government declared its Plan on non-communicable diseases (NCD) Prevention and Control (2017-2025).



The plan identifies reducing premature deaths and improving health-care quality. Under the plan, the government is intended to augment the overall cancer five-year survival rate from 31% to 36% by 2020 and 41% by 2025. Such initiatives promote early cancer screening and diagnosis, which can increase the survival rate of patients. This, in turn, is expected to accelerate the adoption of molecular cytogenetics in the region, as it has contributed to the study and interpretation of cancer karyotypes, specifically using multi color FISH approaches that can even define complex chromosome rearrangements. As a result, it can support the diagnosis, prognosis and treatment decisions for cancer.



Competitive Landscape



The major players in the global molecular cytogenetics market include including Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., and Illumina, Inc., Bio-Rad Laboratories Inc., and F. Hoffman La-Roche AG. Product launches and mergers and acquisitions are considered as some key strategies adopted by the market players to increase market share and gain a competitive advantage. For instance, in January 2020, Oxford Gene Technology (OGT) introduced anNGS panel for constitutional cytogenetics research. The CytoSure Constitutional NGS Panel enables to deliver reliable and accurate detection of copy number variations (CNVs), insertion/deletions (indels), single nucleotide variations (SNVs), and loss of heterozygosity (LOH), such as in mosaic samples. It combines the advantages of NGS and microarrays in one cost-effective assay.This new launch will likely support those laboratories who are focusing on transitioning from arrays to NGS.